Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
A study proposes a model that is able to learn broad aspects of cancer–immune interactions from early phase trial data
Baseline and on-treatment changes in ctDNA may provide an early indication of response to experimental therapies
Studies investigate the discriminatory capacity of existing prognostic scales and the factors associated with survival to help select patients who may benefit from participation in early phase trials
Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system
The 2024 TAT Honorary Awardee Prof. Funda Meric-Bernstam discusses progress made and how to overcome current obstacles in the field
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.